Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Items 101–200 of 452
The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer
Parida, S., & Sharma, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.001 · Cited by 116
“Anthracycline agents on the other hand, require activation of FPR1 on dendritic cells via endogenous ligand annexin A1 from dying cancer cells [79].”
BackgroundAnnexin A1 as a Regulator of Immune Response in Cancer
Araújo, T. G., Mota, S. T. S., Ferreira, H. S. V., Ribeiro, M. A., Goulart, L. R., & Vecchi, L. (2021) · Cells · doi:10.3390/cells10092245 · Cited by 121
Beneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 111
Self-citationMyeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity
Huang, Y., Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0510-3 · Cited by 115
Self-citationMolecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 112
Bloy, N., Garcia, P., Laumont, C. M., Pitt, J. M., Sistigu, A., Stoll, G., Yamazaki, T., Bonneil, E., Buqué, A., Humeau, J., et al. (2017) · Immunological Reviews · doi:10.1111/imr.12582 · Cited by 103
Self-citationCellular cytotoxicity is a form of immunogenic cell death
Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 115
Yamazaki, T., Pitt, J. M., Vétizou, M., Marabelle, A., Flores, C., Rekdal, Ø., Kroemer, G., & Zitvogel, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.35 · Cited by 109
Self-citationMardi, A., Shirokova, A. V., Mohammed, R. N., Keshavarz, A., Zekiy, A. O., Thangavelu, L. P., Mohammad, T. A. M., Marofi, F., Shomali, N., Zamani, A., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02585-z · Cited by 109
Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy
Liu, T., Pei, P., Shen, W., Hu, L. T., & Yang, K. (2023) · Small Methods · doi:10.1002/smtd.202201401 · Cited by 120
Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress
Humeau, J., Sauvat, A., Cerrato, G., Xie, W., Loos, F., Iannantuoni, F., Bezu, L., Lévesque, S., Paillet, J., Pol, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911622 · Cited by 95
“ATP, ANXA1, CALR, and HMGB1 interact with four receptor types, namely, purinergic P2Y2 or P2X7 receptors (Ghiringhelli et al, 2009), formyl peptide receptor-1 (FPR1) (Vacchelli et al, 2015), CD91 (Garg et al, 2012), and toll-like receptor 4 (TLR4) (Apetoh et al, 2007; Yamazaki et al, 2014), respectively, that are pres…”
BackgroundInfluentialSelf-citationDecoding immunogenic cell death from a dendritic cell perspective
Janssens, S., Rennen, S., & Agostinis, P. (2023) · Immunological Reviews · doi:10.1111/imr.13301 · Cited by 113
“In addition, cDAMPs can stimulate innate immune cells by binding to purinergic P2 receptors (e.g., ATP), low-density lipoprotein receptor-related protein 1 (LRP1) (i.e., CRT and HSPs), formyl peptide receptor 1 (FPR1) (i.e., ANXA1), the receptor for advanced glycation end products (RAGE) (i.e., HMGB1), and CLEC9A/DNGR…”
BackgroundChen, J., Jin, Z., Zhang, S., Zhang, X., Li, P., Yang, H., & Ma, Y. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00956-0 · Cited by 104
Self-citation3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 109
Self-citationOrgans on chip approach: a tool to evaluate cancer -immune cells interactions
Biselli, E., Agliari, E., Barra, A., Bertani, F. R., Gerardino, A., De Ninno, A., Mencattini, A., Di Giuseppe, D., Mattei, F., Schiavoni, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13070-3 · Cited by 91
Self-citationToward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.-K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 88
Andreone, S., Spadaro, F., Buccione, C., Mancini, J., Tinari, A., Sestili, P., Gambardella, A. R., Lucarini, V., Ziccheddu, G., Parolini, I., et al. (2019) · Cancers · doi:10.3390/cancers11111664 · Cited by 102
Self-citationFormyl peptide receptor 1 signaling potentiates inflammatory brain injury
Li, Z., Li, Y., Han, J., Zhu, Z., Li, M., Liu, Q., Wang, Y., & Shi, F. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9890 · Cited by 96
Huang, F., Lei, J., Sun, Y., Yan, F., Chen, B., Zhang, L., Lu, Z., Cao, R. Y., Lin, Y., Wang, C.-C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1446720 · Cited by 94
“ICD renders tumor cells ‘visible’ to the immune system and, in particular, to DCs that phagocytose dying tumor cells and then initiate a strong antitumor immune response.(7-12) Cancer cells undergoing ICD generally experience endoplasmic reticulum stress (ER stress),”
BackgroundZhuang, Y., Wang, L., Guo, J., Sun, D., Wang, Y., Liu, W., Xu, H. E., & Zhang, C. (2022) · Nature Communications · doi:10.1038/s41467-022-28586-0 · Cited by 87
Immune recognition of irradiated cancer cells
Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 92
Xu, C., Yu, Y., Sun, Y., Kong, L., Yang, C., Hu, M., Yang, T., Zhang, J., Hu, Q., & Zhang, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201905213 · Cited by 84
FPR1 is the plague receptor on host immune cells
Osei‐Owusu, P., Charlton, T. M., Kim, H. K., Missiakas, D. M., & Schneewind, O. (2019) · Nature · doi:10.1038/s41586-019-1570-z · Cited by 85
Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy
Zhao, L., Zheng, R., Liu, L., Chen, X., Guan, R., Ni, Y., Chen, A., Yu, X., Cheng, H. B., & Li, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120970 · Cited by 83
Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
Palanivelu, L., Liu, C., & Lin, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038226 · Cited by 106
“Besides, a loss-of-function polymorphic mutation in FPR1 reduced the overall survival and progression-free survival in breast and colorectal cancer patients receiving anthracycline or oxaliplatin-based chemotherapy (38).”
BackgroundeIF2α phosphorylation: A hallmark of immunogenic cell death
Bezu, L., Sauvat, A., Humeau, J., Leduc, M., Kepp, O., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431089 · Cited by 80
“This apoptotic ICD has turned out to determine the long-term effects of chemotherapy beyond treatment discontinuation relying on the induction of an effective anticancer immune response.(2,3) It is coupled to a premortem autophagic response (that facilitates lysosomal ATP secretion), an endoplasmic reticulum (ER) stre…”
BackgroundSelf-citationFidelle, M., Yonekura, S., Picard, M., Cogdill, A., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 81
Self-citationLurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Xie, W., Forveille, S., Iribarren, K., Sauvat, A., Senovilla, L., Wang, Y., Humeau, J., Perez-Lanzon, M., Zhou, H., Martínez-Leal, J. F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1656502 · Cited by 79
Self-citationExpansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis
Arimoto, K., Miyauchi, S., Troutman, T. D., Zhang, Y., Liu, M., Stoner, S. A., Davis, A. G., Fan, J.-B., Huang, Y.-J., Yan, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35348-5 · Cited by 91
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer
Qian, X., Huang, Y., Ye, Z., Gao, B., Qian, Z., Ding, Y., Mao, Z., Du, Y., & Wang, W. (2024) · ACS Nano · doi:10.1021/acsnano.4c02947 · Cited by 83
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 82
Self-citationGold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models
Humeau, J., Lévesque, S., Kroemer, G., & Pol, J. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8885-3_21 · Cited by 92
Self-citationAnnexin A1: shifting the balance towards resolution and repair
Leoni, G., & Nusrat, A. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0180 · Cited by 84
Fumet, J.-D., Limagne, E., Thibaudin, M., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12092637 · Cited by 85
“Annexin-1 binds to formyl peptide receptor 1 (FRP1) on dendritic cells, which then promote stable interactions between dying cancer cells and presenting cells [17].”
BackgroundDanger signals: Chemotherapy enhancers?
Rivera Vargas, T., & Apetoh, L. (2017) · Immunological Reviews · doi:10.1111/imr.12581 · Cited by 74
The renaissance of anti‐neoplastic immunity from tumor cell demise
Ma, Y., Pitt, J. M., Li, Q., & Yang, H. (2017) · Immunological Reviews · doi:10.1111/imr.12586 · Cited by 73
Self-citationLucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., Mattia, G., Zanetti, C., Parolini, I., Bracci, L., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.024 · Cited by 77
“…approach, a microfluidics-based technology recently described in our laboratory as a reliable in vivo-like system for investigating the crosstalk between immune cells and cancerous cells (BoussommierCalleja et al., 2016; Businaro et al., 2013; Mattei et al., 2014; Vacchelli et al., 2015).”
BackgroundMethodSelf-citationAutophagy in natural and therapy-driven anticancer immunosurveillance
Pietrocola, F., Bravo-San Pedro, J. M., Galluzzi, L., & Kroemer, G. (2017) · Autophagy · doi:10.1080/15548627.2017.1310356 · Cited by 73
Self-citationPD‐1 Blockade for Improving the Antitumor Efficiency of Polymer–Doxorubicin Nanoprodrug
Gao, F., Zhang, C., Qiu, W., Dong, X., Zheng, D., Wu, W. H., & Zhang, X. (2018) · Small · doi:10.1002/smll.201802403 · Cited by 74
Inflammation-on-a-Chip: Probing the Immune System Ex Vivo
Irimia, D., & Wang, X. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.03.011 · Cited by 70
Caronni, N., Piperno, G. M., Simoncello, F., Romano, O., Vodret, S., Yanagihashi, Y., Dress, R. J., Dutertre, C., Bugatti, M., Bourdeley, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22535-z · Cited by 76
Sun, Z., Deng, G., Peng, X., Xu, X., Liu, L., Peng, J., Ma, Y., Zhang, P., Wen, A., Wang, Y., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121228 · Cited by 70
Self-citationStrategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 67
“These include cell surface calreticulin and other endoplasmic reticulum (ER) chaperones exposed following the unfolded protein response, autophagy-mediated or conventional secretion of ATP, interleukin-1β (IL-1β) secretion as a result of inflammasome signaling, release of high-mobility group box 1 (HMGB1), and cell su…”
BackgroundKumar, V., & Varghese, S. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801198 · Cited by 68
Cell death pathologies: targeting death pathways and the immune system for cancer therapy
Pentimalli, F., Grelli, S., Daniele, N. D., Melino, G., & Amelio, I. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0052-x · Cited by 75
Hernández, Á., Juanes‐Velasco, P., Landeira‐Viñuela, A., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Cancers · doi:10.3390/cancers13112821 · Cited by 76
“Lack of functional ANXA1 or single polymorphism in FPR1 in patients hinders the immune response mediated by ICD inducers [56].”
BackgroundThe emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans
Moreau, J.-F., Pradeu, T., Grignolio, A., Nardini, C., Castiglione, F., Tieri, P., Capri, M., Salvioli, S., Taupin, J.-L., Garagnani, P., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.005 · Cited by 67
Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
Prete, A. D., Sozio, F., Barbazza, I., Salvi, V., Tiberio, L., Laffranchi, M., Gismondi, A., Bosisio, D., Schioppa, T., & Sozzani, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113930 · Cited by 72
Stoll, G., Iribarren, K., Michels, J., Leary, A., Zitvogel, L., Cremer, I., & Kroemer, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1177692 · Cited by 65
Self-citationStimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
Amiri, M., Molavi, O., Sabetkam, S., Jafari, S., & Montazersaheb, S. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03058-7 · Cited by 73
The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K.-D., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 62
Li, C., You, X., Xu, X., Wu, B., Liu, Y., Tong, T., Chen, J., Li, Y., Dai, C., Ye, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202104134 · Cited by 64
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Cruickshank, B. M., Giacomantonio, M., Marcato, P., McFarland, S. A., Pol, J. G., & Gujar, S. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00654 · Cited by 63
Li, Q., Liu, J., Fan, H., Shi, L., Deng, Y., Zhao, L., Xiang, M., Xu, Y., Jiang, X., Wang, G., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120388 · Cited by 63
Vacchelli, E., Enot, D. P., Pietrocola, F., Zitvogel, L., & Kroemer, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0294 · Cited by 59
Self-citationCellular Analysis Using Microfluidics
Sibbitts, J., Sellens, K. A., Jia, S., Klasner, S. A., & Culbertson, C. T. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04519 · Cited by 59
Fiorenza, S., & Turtle, C. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00477-8 · Cited by 66
Role of stress granules in tumorigenesis and cancer therapy
Li, T., Zeng, Z., Fan, C., & Xiong, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189006 · Cited by 64
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 59
“Moreover, the loss-of-function polymorphisms in FPR1 are associated with poor overall survival and metastasis-free survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy [34].”
BackgroundElzoghby, A. O., Samir, O., Emam, H. E., Soliman, A., Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., & Nasr, M. L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.022 · Cited by 58
“The formyl peptide receptor, in conjunction with its soluble ligand annexin A1 (secreted by cancer cells), orchestrates the chemo-tactic activity of DCs towards dying bodies, thus facilitating faster antigen processing and presentation 142 .”
BackgroundLee, J., Tak, W. Y., Lee, Y., Heo, M.-K., Song, J.-S., Kim, H.-Y., Park, S. Y., Bae, S. H., Lee, J. H., Heo, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328335 · Cited by 59
“cells that play a critical role in the cell-mediated immune response by stimulating antigen-specific cytotoxic T cells.(9,10) Autologous DCs offer a practical basis for a tumor vaccine,(11,12)”
BackgroundA TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency
Naour, J. L., Liu, P., Zhao, L., Adjemian, S., Sztupinszki, Z. M., Taïeb, J., Mulot, C., Silvin, A., Dutertre, C., Ginhoux, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0465 · Cited by 56
Self-citationDark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation
Jiang, M., Gu, D.-N., Dai, J., Huang, Q., & Tian, L. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.018 · Cited by 57
Targeting Myc-driven stress addiction in colorectal cancer
Saeed, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100963 · Cited by 61
The danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“Annexin A1 (ANXA1) is passively released from the cytoplasm of dead cells, causing the chemotactic approach of DCs via an action of formyl peptide receptor-1 (FPR1) and hence the formation of contacts between DCs and dying or dead cells 58,59 .”
Self-citationCross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
Audsley, K. M., McDonnell, A. M., & Waithman, J. C. (2020) · Cells · doi:10.3390/cells9030565 · Cited by 58
“The distinctive properties of ICD include i) exposure of calreticulin (CRT) and other ER proteins (HSP70, HSP90) at the cell surface, which act as “eat me” signals facilitating antigen uptake by DCs [91,92], ii) secretion of ATP, which promotes recruitment and activation of DCs via interaction with P2RY2 and P2RX7, re…”
BackgroundEosinophils in the Tumor Microenvironment
Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 55
Self-citationEnhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 56
Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
Chiaravalli, M., Spring, A., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2022) · Cells · doi:10.3390/cells11193033 · Cited by 55
“Other factors favouring APCs recruitment are the autophagy-dependent secretion of adenosine triphosphate (ATP), which binds to the purinergic receptor P2Y2 (P2YR2) on DC precursors [26], and the passive liberation of the cytosolic protein annexin A1 (ANXA1), which guides DCs to dying cells and facilitates their physic…”
BackgroundCancer cell death: Cell-autonomous and immunogenic dimensions
Galluzzi, L., Kepp, O., Zitvogel, L., Tang, D., & Kroemer, G. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.005 · Cited by 76
Self-citationIdentification of pharmacological agents that induce HMGB1 release
Liu, P., Zhao, L., Loos, F., Iribarren, K., Lachkar, S., Zhou, H., Gomes-da-Silva, L. C., Chen, G., Bezu, L., Boncompain, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14848-1 · Cited by 54
Self-citationMicrofluidic technologies for immunotherapy studies on solid tumours
Paterson, K., Zanivan, S. R., Glasspool, R. M., Coffelt, S. B., & Zagnoni, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01305f · Cited by 54
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49
“Furthermore, tumor cell death leads to the release of immunostimulatory molecules such as ATP and Annexin A1 able to recruit DCs in the tumor microenvironment [47,48].”
BackgroundLu, J., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Huang, Y., Wu, M., Li, C., Kong, M., Zhao, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24170-0 · Cited by 48
Kepp, O., Zitvogel, L., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1795995 · Cited by 49
Self-citationLi, Q., Xu, L., Zhu, J., Zhong, Y., Yang, J., Wang, J., & Tan, H. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7530794 · Cited by 66
“The DC carries out antigen uptake and presents it to T cells [56].”
BackgroundImmunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2018) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2018.09.002 · Cited by 52
Kong, Y., Ma, Y., Zhao, X., Pan, J., Xu, Z. Z., & Zhang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638873 · Cited by 51
“Tumor cell nucleic acid derivatives and extracellular annexin A1 have important roles in initiating ICD and affect the strength and durability of adaptive antitumor immune response (21, 22).”
BackgroundSelf-citationTargeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 53
Oncoimmunology Meets Organs-on-Chip
Mattei, F., Andreone, S., Mencattini, A., Ninno, A. D., Businaro, L., Martinelli, E., & Schiavoni, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.627454 · Cited by 51
“…aimed to assess the effects of pharmacological treatments for cancer therapy by using an on chip approach is represented by a study addressing the role of formyl peptide receptor 1 (FPR1)/annexin a1 (Anxa1) axis in anti-tumor response to anthracycline-based chemotherapy (Vacchelli et al., 2015).”
BackgroundMethodInfluentialSelf-citationImmunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
Matsushita, M., & Kawaguchi, M. (2018) · Journal of Oncology · doi:10.1155/2018/8653489 · Cited by 47
Anticancer effects of anti-CD47 immunotherapy in vivo
Iribarren, K., Buqué, A., Mondragón, L., Xie, W., Lévesque, S., Pol, J. G., Zitvogel, L., Kepp, O., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1550619 · Cited by 46
“The latter was administered at a dose that is efficient against many transplantable mouse cancers.(10,23,26) However, the combination treatment did not further increase the anti-CD47-induced control of tumor growth (Figure 3(b)–f) or overall survival (Figure 3(g)).”
BackgroundSelf-citationContribution of annexin A1 to anticancer immunosurveillance
Baracco, E. E., Stoll, G., Endert, P. V., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1647760 · Cited by 47
Self-citationResisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
“highlighted the importance of the presence of the protein Formyl Peptide Receptor-1 (FPR-1) on DCs in breast and colon cancer, as its absence leads to a decrease in overall survival due to a lack of anticancer immune response because of the failure of antigen presentation and hence the failure of T-cell activation [71…”
BackgroundCell migration in microengineered tumor environments
Um, E., Oh, J. M., Granick, S., & Cho, Y. (2017) · Lab on a Chip · doi:10.1039/c7lc00555e · Cited by 47
Comes, M. C., Casti, P., Mencattini, A., Giuseppe, D. D., Mermet‐Meillon, F., Ninno, A. D., Parrini, M. C., Businaro, L., Natale, C. D., & Martinelli, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-42475-5 · Cited by 45
Self-citationCell Death in the Tumor Microenvironment: Implications for Cancer Immunotherapy
Gadiyar, V., Lahey, K. C., Calianese, D. C., Devoe, C., Mehta, D., Bono, K. R., Desind, S. Z., Davra, V., & Birge, R. B. (2020) · Cells · doi:10.3390/cells9102207 · Cited by 48
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 51
Cascarano, P., Comes, M. C., Mencattini, A., Parrini, M. C., Piccolomini, E. L., & Martinelli, E. (2021) · Medical Image Analysis · doi:10.1016/j.media.2021.102124 · Cited by 45
Hennequart, M., Pilley, S. E., Labuschagne, C. F., Coomes, J., Mervant, L., Driscoll, P. C., Legrave, N. M., Lee, Y., Kreuzaler, P. A., Macintyre, B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112562 · Cited by 46
Vaes, R. D. W., Reynders, K., Sprooten, J., Nevola, K. T., Rouschop, K. M. A., Vooijs, M., Garg, A. D., Lambrecht, M. L. F., Hendriks, L. E. L., Ručević, M., et al. (2021) · Cancers · doi:10.3390/cancers13246259 · Cited by 42
Conventional type 1 dendritic cells (cDC1) in cancer immunity
Liu, P., Zhao, L., Kroemer, G., & Kepp, O. (2023) · Biology Direct · doi:10.1186/s13062-023-00430-5 · Cited by 50
Self-citationOn-chip recapitulation of the tumor microenvironment: A decade of progress
Giannitelli, S. M., Peluzzi, V., Raniolo, S., Roscilli, G., Trombetta, M., Mozetic, P., & Rainer, A. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122482 · Cited by 45
Zhou, Z., Mai, Y., Zhang, G., Wang, Y., Sun, P., Jing, Z., Li, Z., Xu, Y., Han, B. R., & Liu, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217079 · Cited by 46
Xu, X., Yu, Y., Zhang, W., Ma, W., He, C., Qiu, G., Wang, X., Liu, Q., Zhao, M., Xie, J., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01349-3 · Cited by 44
The ambiguous role of FPR1 in immunity and inflammation
Vacchelli, E., Naour, J. L., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1760061 · Cited by 40
Self-citationMencattini, A., Mattei, F., Schiavoni, G., Gerardino, A., Businaro, L., Natale, C. D., & Martinelli, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00100 · Cited by 40
“Some attempts have been presented with the aim to model cancer–immune interaction (Vacchelli et al., 2015) through time-lapse microscopy analysis.”
BackgroundSelf-citationSIRT1 and gynecological malignancies (Review)
Chen, J., Chen, H., & Pan, L. (2021) · Oncology Reports · doi:10.3892/or.2021.7994 · Cited by 44
Comparative analysis of protein-protein interaction networks in metastatic breast cancer
Hozhabri, H., Dehkohneh, R. S. G., Razavi, S. M., Razavi, S. M., Salarian, F., Rasouli, A., Azami, J., Shiran, M. G., Kardan, Z., Farrokhzad, N., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0260584 · Cited by 40
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.